Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Interleukin-2 for Mycosis Fungoides or Sezary Syndrome
NCT00005788Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Apr 1997
- Primary completion
- Jan 2002
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Northwestern University. Primary endpoints: Response Rate and Toxicity. Started Apr 1997; status: terminated.
02
Drugs
aldesleukin
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT00005788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005788.